NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy

J Natl Compr Canc Netw. 2011 Feb;9 Suppl 1(0 1):S1-29. doi: 10.6004/jnccn.2011.0124.

Abstract

The outcome of patients with metastatic renal cell carcinoma has been substantially improved with administration of the currently available molecularly targeted therapies. However, proper selection of therapy and management of toxicities remain challenging. NCCN convened a multidisciplinary task force panel to address the clinical issues associated with these therapies in attempt to help practicing oncologists optimize patient outcomes. This report summarizes the background data presented at the task force meeting and the ensuing discussion.

MeSH terms

  • Carcinoma, Renal Cell / genetics
  • Carcinoma, Renal Cell / metabolism
  • Carcinoma, Renal Cell / therapy*
  • Clinical Trials as Topic
  • Humans
  • Kidney Neoplasms / genetics
  • Kidney Neoplasms / metabolism
  • Kidney Neoplasms / therapy*
  • Molecular Targeted Therapy / adverse effects
  • Molecular Targeted Therapy / methods*
  • Treatment Outcome